Stage IV EGFR Lung Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; later ALK mutation after progression

Metastatic Site: Bone — pelvis and spine/L5

Living with Stage IV lung cancer on a clinical trial after progression, with current treatment described as working and quality of life improved.

The Patient StoryRead more →

Stage II EGFR Non-Small Cell Lung Cancer: Daniel's Patient Story

Patient Info: Daniel West, Male, 50s | Stage II

Biomarkers: EGFR positive

As of April 2026, Daniel had shown no evidence of active disease for more than 2 years, while remaining on daily osimertinib through June 2026 and receiving checkups and scans every 3 months for stable monitored lung nodules.

MD AndersonRead more →

Stage III EGFR Lung Cancer: Roxanne's Patient Story

Patient Info: Roxanne, Female, 40s | Stage III

Biomarkers: EGFR mutation

Roxanne had Stage III EGFR-mutated lung cancer after surgery found mediastinal lymph-node involvement. As of March 2026, she was living with the long-term effects of surgery, chemotherapy, radiation, and ongoing EGFR-targeted therapy, while also managing the emotional and financial burden of cancer as a single parent.

The Patient StoryRead more →

Stage IV EGFR-positive lung cancer treated for nearly 5 years before progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR L858R mutation

Metastatic Site: liver

The cancer later progressed despite chemotherapy, and he died from lung cancer 4 years and 8 months after diagnosis.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Maggie's Patient Story

Patient Info: Maggie, Female, 60s | Stage IV

Biomarkers: EGFR mutation; MET amplification resistance mutation; MET overexpression

Metastatic Site: Brain

Maggie initially reached no evidence of disease on EGFR-targeted therapy, but later had repeated progression, including MET-amplification resistance and MET overexpression, requiring SBRT, a clinical trial, chemotherapy, and later-line targeted treatment.

The Patient StoryRead more →

Stage I EGFR Lung Cancer: Shira's Survivor Story

Patient Info: Shira, Female | Stage I

Biomarkers: EGFR exon 20 insertion

Shira had Stage IB lung cancer detected early through imaging and treated with surgery alone. Her tumor was later categorized as low risk of recurrence, and she described herself as cancer-free as of February 2026.

The Patient StoryRead more →

EGFR L858R lung adenocarcinoma with rapid neurologic decline

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: EGFR L858R mutation; CK7-positive; Napsin A-positive; TTF-1-positive; p40-negative; Ki-67 about 1%

Metastatic Site: brain parenchyma and meninges

The patient developed rapidly progressive cognitive decline with multifocal brain lesions. Lung biopsy confirmed EGFR L858R lung adenocarcinoma, and she received amivantamab, but neurologic deterioration continued and she died in the fourth month of the disease course.

PubMed CentralRead more →

Stage 4 lung cancer: never-smoker with complete remission

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR20ins mutation; TP53 p.Q192 mutation; PD-L1 TPS 0%; CPS 0%

Metastatic Site: bilateral lungs, mediastinal lymph nodes, bilateral…

The patient had a durable response to high-dose furmonertinib, later developed a right cerebellar metastasis treated with stereotactic radiation, and continued to benefit from furmonertinib as of April 2025 with 27 months of progression-free survival reported.

PubMed CentralRead more →

EGFR R252C multifocal lung cancer responding to afatinib

Patient Info: Anonymized

Biomarkers: EGFR R252C extracellular-domain mutation

Afatinib was associated with suppression of primary tumor growth and extended progression-free survival in a patient with multifocal lung cancer and glioma driven by EGFR R252C. Stage and metastatic sites were not established from the available case summary.

PubMed CentralRead more →

EGFR-Mutant Lung Adenocarcinoma With Bone and Leptomeningeal Metastases

Patient Info: Anonymized, male, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: bone, leptomeninges

In May 2025, leptomeningeal disease remained present and he continued combination chemotherapy with bevacizumab and high-dose furmonertinib, leaving hospital in stable condition after cycle 8.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Jennifer's Patient Story

Patient Info: Jennifer, Female | Stage IV

Biomarkers: EGFR genomic mutation

Metastatic Site: Not reported

Jennifer is alive more than 5.5 years after a Stage IV adenocarcinoma diagnosis, continuing EGFR-targeted treatment and living with ongoing side effects and surveillance needs.

The Patient StoryRead more →

Stage IVA EGFR-mutated lung adenocarcinoma with malignant pleural effusion: stable disease on ivonescimab plus pemetrexed

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion persisted. Later pleural fluid had PD-L1 TPS 40% / CPS 41, low TMB

Metastatic Site: pleura / malignant pleural effusion

As of August 2025, Stage IVA EGFR-mutated lung adenocarcinoma with malignant pleural effusion was stable on ivonescimab plus pemetrexed after prior progression on gefitinib, almonertinib, and ivonescimab monotherapy.

PubMed CentralRead more →

Stage IVB EGFR L861R lung adenocarcinoma treated with afatinib, osimertinib, and chemotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: EGFR L861R mutation; CEA 5.5 ng/mL; CYFRA 21-1 5.1 ng/mL

Metastatic Site: lymph nodes, lung, bone

As of September 2025, the patient remained alive 27 months after diagnosis after multiple EGFR-targeted and chemotherapy lines.

PubMed CentralRead more →

Stage IV EGFR-mutant lung cancer: treatment and follow-up story

Patient Info: Anonymized, Female | Stage IV

Biomarkers: EGFR-mutated

As of November 2025, she was newly living with Stage IV EGFR-mutated lung cancer after starting first-generation targeted therapy on 5 March and managing treatment side effects during the first 3 months.

YouTube (ZH search)Read more →

EGFR Non-Small Cell Lung Cancer: Michelle's Patient Story

Patient Info: Michelle Vacca, Female, 40s

Biomarkers: EGFR mutation at recurrence; later rare mutation not named

As of November 2025, Michelle still actively had recurrent NSCLC, but her disease had remained stable on targeted therapy and an investigational kinase inhibitor clinical trial, allowing good quality of life.

City of HopeRead more →

Four EGFR-Mutated Lung Cancers That Changed Form After Osimertinib

Patient Info: Anonymized, female, 50s

Biomarkers: EGFR exon 19 deletion; TP53 p.D259V

The cancer progressed after second-line treatment and later topotecan, and she died 2 months after topotecan ended.

PubMed CentralRead more →

Four EGFR-Mutated Lung Cancers That Changed Form After Osimertinib — Case 2

Patient Info: Anonymized, female, 60s

Biomarkers: EGFR exon 19 deletion; TP53 p.R110P; acquired MET amplification

The disease progressed after combined targeted therapy, and she died after 7 months of carboplatin, etoposide, and atezolizumab.

PubMed CentralRead more →

Four EGFR-Mutated Lung Cancers That Changed Form After Osimertinib — Case 3

Patient Info: Anonymized, male, 70+

Biomarkers: EGFR mutation; TP53 p.Y220C

After small cell transformation and progression, he received palliative care and died 1 month later.

PubMed CentralRead more →

Four EGFR-Mutated Lung Cancers That Changed Form After Osimertinib — Case 4

Patient Info: Anonymized, female, 70+

Biomarkers: EGFR exon 19 deletion; TP53 p.L201fs

She died 3 months after starting carboplatin and pemetrexed for the transformed cancer.

PubMed CentralRead more →

Stage IVA EGFR-mutant lung adenocarcinoma: response to triple targeted therapy and surgery

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR exon 19 deletion; acquired BRAF V600E mutation in progressive lesion while EGFR exon 19 deletion persisted

Metastatic Site: pleura, pulmonary metastases; mediastinal and left…

As of May 2025, she continued osimertinib, dabrafenib, and trametinib after segmentectomy/lymphadenectomy, with 1% viable residual tumor in resected lung lesions, complete nodal pathologic response, and no disease progression.

PubMed CentralRead more →

EGFR L858R lung adenocarcinoma presenting as rectal and peritoneal metastases

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Rectal/peritoneal tumors supported lung origin. Key result: EGFR L858R with TP53 mutations; no other actionable lung alteration reported.

Metastatic Site: rectum; peritoneum; omentum; mesentery; colonic wall

After transverse colostomy and confirmation of EGFR L858R-mutant lung adenocarcinoma metastasis, aumolertinib led to clinical stabilization; palliative radiotherapy was later given to the rectal lesion, but long-term follow-up was not yet available.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Emily's Patient Story

Patient Info: Emily, Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Right lung; right 8th rib; sacrum; pancreas; brain

Emily had Stage IV EGFR-mutated lung cancer treated with daily targeted therapy, 4 rounds of chemotherapy, and later radiation. As of September 2025, she felt well and described being almost/basically in remission, but her cancer remained treatable rather than curable and she continued daily targeted therapy.

The Patient StoryRead more →

EGFR-Mutant Stage IV Lung Cancer Treated After Osimertinib-Related Lung Toxicity

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; later EGFR T790M resistance mutation

Metastatic Site: brain, lungs, bones, left adrenal gland, meninges

The latest documented treatment was a lower-dose osimertinib rechallenge with corticosteroids, which reduced the tumor without recurrence of the prior interstitial lung disease.

PubMed CentralRead more →

Stage IIIA EGFR lung adenocarcinoma: no recurrence after early osimertinib stop

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: EGFR exon 19 deletion mutation; elevated KL-6 and SP-D during interstitial lung disease episode

During 9 months of follow-up after osimertinib was stopped, she had no recurrence of interstitial lung disease, pulmonary embolism, or non-small cell lung cancer.

PubMed CentralRead more →